Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, No 386, Ta-Chung 1st Road, 813, Kaohsiung, Taiwan, Republic of China.
Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, Taiwan, Republic of China.
BMC Musculoskelet Disord. 2022 Nov 4;23(1):954. doi: 10.1186/s12891-022-05906-5.
BACKGROUND: Intraarticular plasma-rich platelet (PRP) and hyaluronic acid (HA) have each been shown to be effective for treating knee osteoarthritis (OA). Evidence supporting the combination therapy is controversial. This study aimed to investigate the efficacy of a single intraarticular PRP injection combined with different HAs in patients with knee OA. METHODS: In this prospective randomized-controlled trial, 99 patients with Kellgren-Lawrence grade 2 knee OA with average knee pain ≥ 30 mm on a 0-100 mm pain visual analog scale (VAS) were randomized into two groups. The PRP + Artz group received a single intraarticular HA (Artz, 2.5 ml, 10 mg/ml) followed by 3 ml PRP (n = 50). The PRP + HYAJOINT Plus group received a single intraarticular cross-linked HA (HYAJOINT Plus, 3 ml, 20 mg/ml) followed by 3 ml PRP (n = 49). All patients were evaluated before and at 1, 3 and 6 months after injections. The primary outcome was the VAS pain reduction from baseline at 6 months. Secondary outcome measures included Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequesne index, single leg stance (SLS) test and patient satisfaction. RESULTS: Ninety-five patients were analyzed by intention-to-treat analysis. Both groups improved significantly in VAS pain, WOMAC, Lequesne index and SLS at 1, 3 and 6 months post intervention (p < 0.05). Between-group comparisons showed no significant differences at most follow-up time points, except better improvements in Lequesne index at 1 month (p = 0.003) and WOMAC-stiffness score at 6 months (p = 0.020) in the PRP + Artz group, and superiority in SLS at 1, 3 and 6 months in the PRP+ HYAJOINT Plus group (p < 0.001, p = 0.003 and p = 0.004). Additional Johnson-Neyman analyses showed that among the patients with baseline WOMAC-pain score > 8.5, WOMAC-function score > 21.7 and WOMAC-total score > 32.0, respectively, those treated with PRP + HYAJOINT Plus injections had better effects in WOMAC-pain, WOMAC-function and WOMAC-total scores than those treated with PRP + Artz at 3 months postinjection (p < 0.05). Both groups reported high satisfaction. No serious adverse events occurred during the study. CONCLUSIONS: A single PRP injection combined with Artz or HYAJOINT Plus is effective and safe for 6 months in patients with knee OA. Both injection regimens are potential treatment options for knee OA. Further studies are needed to confirm these results. TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov (NCT04931719), retrospectively. Date of registration 18/6/2021. NAME OF TRIAL REGISTRY: Comparing efficacy of single PRP combined with different hyaluronans for knee osteoarthritis. LEVEL OF EVIDENCE: Therapeutic Level 1.
背景:关节内富含血小板的血浆(PRP)和透明质酸(HA)已被证明对治疗膝关节骨关节炎(OA)均有效。支持联合治疗的证据存在争议。本研究旨在探讨单次关节内 PRP 注射联合不同 HA 治疗膝骨关节炎患者的疗效。
方法:这是一项前瞻性随机对照临床试验,纳入了 99 例 Kellgren-Lawrence 分级为 2 级、膝关节平均疼痛≥30mm(0-100mm 疼痛视觉模拟评分[VAS])的膝骨关节炎患者,随机分为两组。PRP+Artz 组接受单次关节内 HA(Artz,2.5ml,10mg/ml)注射,随后注射 3ml PRP(n=50)。PRP+HYAJOINT Plus 组接受单次关节内交联 HA(HYAJOINT Plus,3ml,20mg/ml)注射,随后注射 3ml PRP(n=49)。所有患者在注射前及注射后 1、3 和 6 个月进行评估。主要结局为 6 个月时 VAS 疼痛从基线的缓解率。次要结局指标包括 Western Ontario 和 McMaster 大学骨关节炎指数(WOMAC)、Lequesne 指数、单腿站立测试(SLS)和患者满意度。
结果:95 例患者进行意向治疗分析。两组患者在注射后 1、3 和 6 个月时 VAS 疼痛、WOMAC、Lequesne 指数和 SLS 均显著改善(p<0.05)。在大多数随访时间点,两组间比较差异无统计学意义,但在 1 个月时 Lequesne 指数(p=0.003)和 6 个月时 WOMAC 僵硬评分(p=0.020)改善更好,在 1、3 和 6 个月时 SLS 改善更优(p<0.001,p=0.003 和 p=0.004),差异有统计学意义。进一步的 Johnson-Neyman 分析显示,在基线 WOMAC 疼痛评分>8.5、WOMAC 功能评分>21.7 和 WOMAC 总分>32.0的患者中,与 PRP+Artz 治疗相比,PRP+HYAJOINT Plus 治疗在 3 个月时的 WOMAC 疼痛、WOMAC 功能和 WOMAC 总分改善更优(p<0.05)。两组患者均报告满意度高。研究期间未发生严重不良事件。
结论:单次 PRP 注射联合 Artz 或 HYAJOINT Plus 治疗膝关节骨关节炎在 6 个月时有效且安全。两种注射方案均为膝关节骨关节炎的潜在治疗选择。需要进一步的研究来证实这些结果。
试验注册:该研究在 ClinicalTrials.gov(NCT04931719)上进行了注册,注册日期为 2021 年 6 月 18 日。
试验注册名称:比较单次 PRP 联合不同透明质酸治疗膝骨关节炎的疗效。
临床试验证据级别:治疗性 1 级。
J Orthop Surg Res. 2020-9-11
Arthrosc Sports Med Rehabil. 2024-8-23
Knee Surg Sports Traumatol Arthrosc. 2021-12
Osteoarthritis Cartilage. 2020-3
Knee Surg Sports Traumatol Arthrosc. 2020-9